IceCure Medical has secured the Japan Patent Office’s Notice of Allowance for a patent application titled ‘Cryogen Flow Control’ related to its ProSense System, a minimally-invasive cryoablation technology.
ProSense is designed to destroy tumours, providing an alternative to surgical removal, by freezing them.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The patent is set to remain in effect until 2042, once granted.
It is due to receive approval in other major markets, including the EU and the US.
The system’s advanced cryogen flow control, which has now been recognised by the JPO, is critical for maintaining precise temperature control during procedures. This ensures the safety of surrounding tissues and enhances treatment effectiveness.
The ProSense Cryoablation System is designed to destroy both benign and cancerous lesions in various organs such as the breast, kidney, lung, and liver.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt utilises liquid nitrogen for effective tumour destruction, creating large lethal zones.
The system is not only effective but also reduces recovery time, pain, and the risks associated with surgical procedures. The transportable design of ProSense and its use of liquid nitrogen make it suitable for office-based procedures, especially for breast tumours.
IceCure CEO Eyal Shamir said: “We believe that cryogen flow control will be instrumental in enabling practitioners to perform accurate navigation and cryo-mapping to achieve cryoablation efficiency and expand cryoablation treatment to more clinical applications in the future.
“As a leader in cryoablation technology worldwide, we continue to innovate and build our IP portfolio. This Notice of Allowance in Japan further fortifies our position in an important market, served in partnership with our in-country distributor, Terumo.”
Recently, ProSense demonstrated it can reduce the sizes of the breast cancer tumour by 100% after 12 months, in an independent study.
